Portal de Periódicos da CAPES

Hyper-CVAD Plus Ponatinib as Frontline Therapy in Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase II Trial

2017; Elsevier BV; Volume: 17; Linguagem: Inglês

10.1016/j.clml.2017.07.021

2152-2650

Abhishek Maiti, Hagop M. Kantarjian, Farhad Ravandi, Nicholas J. Short, Naval Daver, Naveen Pemmaraju, Deborah A. Thomas, Musa Yılmaz, Tapan M. Kadia, Koji Sasaki, Rebecca Garris, Guillermo Garcia‐Manero, Courtney D. DiNardo, Marina Konopleva, Zeev Estrov, Nitin Jain, William Weirda, Vicky Jeanis, Jorge E. Cortés, Susan O’Brien, Elias Jabbour,

Chronic Lymphocytic Leukemia Research

Chemotherapy in combination with tyrosine kinase inhibitors (TKI) are effective in Ph+ ALL. Ponatinib is a third-generation TKI which potently inhibits the BCR-ABL tyrosine kinase. Single-agent ponatinib has high activity in patients with Ph+ ALL but has dose-dependent cardiovascular toxicity.